Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, has completed its previously announced acquisition of Mobidiag Oy, an innovator in near-patient, acute care molecular diagnostic testing, for an enterprise value of approximately $808 million. Mobidiag provides near-patient, molecular diagnostic instruments and tests for acute care conditions including gastrointestinal and respiratory infections, antimicrobial resistance management, and healthcare associated infections.
Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, announced Thursday it has completed its previously announced acquisition of Ritter GmbH and its affiliates. Headquartered in Schwabmünchen, Germany, Ritter is the fastest growing manufacturer of high-quality robotic and liquid handling consumables, including conductive pipette tips engineered to exacting standards.
A new method for identifying illness from blood samples could have seismic implications for the multi-billion dollar diagnostics testing sector. Covid-19 has placed unprecedented attention on the importance of fast, reliable medical tests. Scientists are working on low-cost, rapid technology combining genes and immunology to identify diseases.
With slow vaccination rates threatening the likelihood of herd immunity, companies and federal and state governments are pouring billions of dollars into a future in which Covid-19 testing remains a key component for resuming normal life in the U.S. Public-health officials increasingly expect pockets of America will remain largely unvaccinated. That has businesses and health officials counting on testing as a means for controlling the virus.
AliveCor, the global leader in FDA-cleared personal electrocardiogram (ECG) technology and services, announced Wednesday that it has acquired the independent diagnostic testing facility (IDTF) CardioLabs, a leading monitoring and cardiac diagnostic service provider. The acquisition is a cornerstone of AliveCor’s mission to extend its comprehensive cardiological services to patients who are prescribed monitoring devices by their healthcare providers. With the acquisition, AliveCor now manages CardioLabs’ U.S.-based healthcare provider customers and plans to expand the service to new customers in the coming months.
Apollo Medical Holdings, Inc. (“ApolloMed,” and together with its subsidiaries and affiliated entities, the “Company”) (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on value-based care, today announced that the Company has entered into a definitive agreement with Sun Clinical Laboratories (“Sun Labs”), under which ApolloMed will purchase controlling interests in Sun Labs for $4.0 million. Sun Labs is a CLIA-certified full-service lab that operates 19 locations across the San Gabriel Valley in southern California.
Quest Diagnostics (NYSE:DGX) and Mercy announced Tuesday that Quest has completed its previously announced acquisition of the outreach laboratory services business of Mercy in an all-cash asset transaction. With the transaction, Mercy’s outreach laboratory services will transition to Quest’s full-service laboratory in Lenexa, Kansas and the company’s network of rapid response laboratories across the Midwest. Mercy will continue to wholly own and operate its hospital laboratories for tests connected to inpatient and hospital-based outpatient care needs.
On May 28, 2021, Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, completed the sale of its wholly-owned subsidiary, Myriad myPath, LLC, which owns the laboratory that offers the myPath Melanoma test, to Castle Biosciences, Inc for $32.5 million in cash.
Veracyte, Inc. (Nasdaq: VCYT) today announced it has reached the terms of an agreement to acquire HalioDx in a transaction to further accelerate growth and strengthen Veracyte’s global leadership in cancer diagnostics. HalioDx is an immuno-oncology diagnostics company providing oncologists and drug development organizations with first-in-class diagnostic products and services to guide cancer care and contribute to precision medicine.
Generational Capital Markets is pleased to announce the sale of Navix Holdings Corp. and its subsidiary, Navix Diagnostix, Inc. (a portfolio company of Prospect Partners) to a Private Investment Firm. The acquisition closed April 30, 2021. Prospect Partners is a leading lower-middle-market private equity firm based in Chicago. Located in Taunton, Massachusetts, Navix Diagnostix, Inc. (Navix) is the market leader in providing outsourced cardiovascular services, specializing in the management of noninvasive vascular labs.
What We Do
Who We Are
How We Work
Who We Help
Get In Touch
Connect With Us
Subscribe to Our Daily Note
We publish a Daily Note that aggregates M&A activity, notable developments, regulatory changes, and conferences we deem to be of interest to our partners. It is a quick afternoon read and an easy way to keep your finger on the pulse of the healthcare space. Please fill in your name and email address below if you wish to subscribe.